Titre : Recombinases

Recombinases : Questions médicales fréquentes

Termes MeSH sélectionnés :

Visual Fields
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Recombinases : Questions médicales les plus fréquentes", "headline": "Recombinases : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Recombinases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-06", "dateModified": "2025-03-01", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Recombinases" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Enzymes", "url": "https://questionsmedicales.fr/mesh/D004798", "about": { "@type": "MedicalCondition", "name": "Enzymes", "code": { "@type": "MedicalCode", "code": "D004798", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Holliday junction resolvases", "alternateName": "Holliday Junction Resolvases", "url": "https://questionsmedicales.fr/mesh/D045565", "about": { "@type": "MedicalCondition", "name": "Holliday junction resolvases", "code": { "@type": "MedicalCode", "code": "D045565", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.739.250" } } }, { "@type": "MedicalWebPage", "name": "Integrases", "alternateName": "Integrases", "url": "https://questionsmedicales.fr/mesh/D019426", "about": { "@type": "MedicalCondition", "name": "Integrases", "code": { "@type": "MedicalCode", "code": "D019426", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.739.500" } } } ], "about": { "@type": "MedicalCondition", "name": "Recombinases", "alternateName": "Recombinases", "code": { "@type": "MedicalCode", "code": "D045522", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Ahmed Abd El Wahed", "url": "https://questionsmedicales.fr/author/Ahmed%20Abd%20El%20Wahed", "affiliation": { "@type": "Organization", "name": "Division of Microbiology and Animal Hygiene, Georg-August University, D-37077 Goettingen, Germany." } }, { "@type": "Person", "name": "Jonas Kissenkötter", "url": "https://questionsmedicales.fr/author/Jonas%20Kissenk%C3%B6tter", "affiliation": { "@type": "Organization", "name": "Division of Microbiology and Animal Hygiene, Georg-August University, D-37077 Goettingen, Germany." } }, { "@type": "Person", "name": "Susanne Böhlken-Fascher", "url": "https://questionsmedicales.fr/author/Susanne%20B%C3%B6hlken-Fascher", "affiliation": { "@type": "Organization", "name": "Division of Microbiology and Animal Hygiene, Georg-August University, D-37077 Goettingen, Germany." } }, { "@type": "Person", "name": "Matthew S Forrest", "url": "https://questionsmedicales.fr/author/Matthew%20S%20Forrest", "affiliation": { "@type": "Organization", "name": "TwistDx(TM) Limited, Cambridge, United Kingdom." } }, { "@type": "Person", "name": "Maciej Paszkowski-Rogacz", "url": "https://questionsmedicales.fr/author/Maciej%20Paszkowski-Rogacz", "affiliation": { "@type": "Organization", "name": "Medical Systems Biology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Comparing a head-mounted virtual reality perimeter and the Humphrey Field Analyzer for visual field testing in healthy and glaucoma patients.", "datePublished": "2023-10-06", "url": "https://questionsmedicales.fr/article/37803502", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/opo.13229" } }, { "@type": "ScholarlyArticle", "name": "Progressive Paracentral Visual Field Loss at Low Intraocular Pressures Following LASIK.", "datePublished": "2024-06-14", "url": "https://questionsmedicales.fr/article/39141409", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/IJG.0000000000002395" } }, { "@type": "ScholarlyArticle", "name": "Human perception of spatial frequency varies with stimulus orientation and location in the visual field.", "datePublished": "2023-10-17", "url": "https://questionsmedicales.fr/article/37848541", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-023-44673-8" } }, { "@type": "ScholarlyArticle", "name": "Cortical magnification eliminates differences in contrast sensitivity across but not around the visual field.", "datePublished": "2023-03-24", "url": "https://questionsmedicales.fr/article/36961485", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.7554/eLife.84205" } }, { "@type": "ScholarlyArticle", "name": "Smoking Cessation May Reduce Risk of Visual Field Progression in Heavy Smokers.", "datePublished": "2022-08-02", "url": "https://questionsmedicales.fr/article/35939832", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/IJG.0000000000002092" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Enzymes et coenzymes", "item": "https://questionsmedicales.fr/mesh/D045762" }, { "@type": "ListItem", "position": 3, "name": "Enzymes", "item": "https://questionsmedicales.fr/mesh/D004798" }, { "@type": "ListItem", "position": 4, "name": "Recombinases", "item": "https://questionsmedicales.fr/mesh/D045522" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Recombinases - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Recombinases", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Recombinases", "description": "Comment diagnostiquer une déficience en recombinases ?\nQuels tests sont utilisés pour évaluer l'activité des recombinases ?\nLes symptômes peuvent-ils indiquer un problème de recombinases ?\nQuels marqueurs biologiques sont associés aux recombinases ?\nPeut-on détecter des recombinases par imagerie médicale ?", "url": "https://questionsmedicales.fr/mesh/D045522?mesh_terms=Visual+Fields&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Recombinases", "description": "Quels symptômes sont liés à une déficience en recombinases ?\nLes troubles de la recombinaison affectent-ils le système immunitaire ?\nY a-t-il des signes cliniques de dysfonction des recombinases ?\nLes cancers sont-ils liés aux anomalies des recombinases ?\nLes symptômes varient-ils selon le type de recombinase affectée ?", "url": "https://questionsmedicales.fr/mesh/D045522?mesh_terms=Visual+Fields&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Recombinases", "description": "Peut-on prévenir les troubles liés aux recombinases ?\nLes tests génétiques peuvent-ils aider à prévenir les troubles ?\nY a-t-il des recommandations pour les familles à risque ?\nL'éducation sur les maladies génétiques est-elle importante ?\nLes vaccinations peuvent-elles prévenir des complications ?", "url": "https://questionsmedicales.fr/mesh/D045522?mesh_terms=Visual+Fields&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Recombinases", "description": "Quels traitements existent pour les déficiences en recombinases ?\nPeut-on corriger les anomalies des recombinases par des médicaments ?\nLa thérapie génique est-elle efficace pour les troubles liés aux recombinases ?\nLes traitements préventifs sont-ils disponibles pour les troubles de recombinases ?\nLes greffes de cellules souches peuvent-elles aider ?", "url": "https://questionsmedicales.fr/mesh/D045522?mesh_terms=Visual+Fields&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Recombinases", "description": "Quelles complications peuvent survenir avec des troubles de recombinases ?\nLes troubles de recombinases augmentent-ils le risque de cancer ?\nComment les troubles de recombinases affectent-ils la qualité de vie ?\nLes complications sont-elles réversibles ?\nLes troubles de recombinases peuvent-ils affecter la fertilité ?", "url": "https://questionsmedicales.fr/mesh/D045522?mesh_terms=Visual+Fields&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Recombinases", "description": "Quels sont les facteurs de risque pour les troubles de recombinases ?\nL'exposition à des agents environnementaux influence-t-elle les troubles ?\nLes facteurs génétiques jouent-ils un rôle dans les troubles de recombinases ?\nLe sexe influence-t-il le risque de troubles de recombinases ?\nL'âge est-il un facteur de risque pour les troubles de recombinases ?", "url": "https://questionsmedicales.fr/mesh/D045522?mesh_terms=Visual+Fields&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une déficience en recombinases ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de l'ADN peuvent identifier des anomalies." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'activité des recombinases ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de recombinaison in vitro et des analyses de séquençage sont courants." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils indiquer un problème de recombinases ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies immunitaires ou des troubles génétiques peuvent être des indicateurs." } }, { "@type": "Question", "name": "Quels marqueurs biologiques sont associés aux recombinases ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux anormaux de certains ARN ou protéines peuvent signaler des dysfonctionnements." } }, { "@type": "Question", "name": "Peut-on détecter des recombinases par imagerie médicale ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Non, l'imagerie ne peut pas détecter directement les recombinases, mais elle aide à évaluer les effets." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une déficience en recombinases ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des infections fréquentes, des troubles auto-immuns et des cancers peuvent survenir." } }, { "@type": "Question", "name": "Les troubles de la recombinaison affectent-ils le système immunitaire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent entraîner une immunodéficience et une susceptibilité accrue aux infections." } }, { "@type": "Question", "name": "Y a-t-il des signes cliniques de dysfonction des recombinases ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies dans les tests sanguins et des symptômes d'inflammation peuvent apparaître." } }, { "@type": "Question", "name": "Les cancers sont-ils liés aux anomalies des recombinases ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des mutations dans les gènes de recombinases peuvent augmenter le risque de cancers." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de recombinase affectée ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes dépendent du type de recombinase et de son rôle dans l'organisme." } }, { "@type": "Question", "name": "Peut-on prévenir les troubles liés aux recombinases ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes." } }, { "@type": "Question", "name": "Les tests génétiques peuvent-ils aider à prévenir les troubles ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques permettent d'identifier les porteurs et de planifier des interventions." } }, { "@type": "Question", "name": "Y a-t-il des recommandations pour les familles à risque ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les conseils génétiques et le suivi médical régulier sont recommandés pour les familles à risque." } }, { "@type": "Question", "name": "L'éducation sur les maladies génétiques est-elle importante ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une meilleure compréhension des maladies génétiques peut aider à la prévention et à la gestion." } }, { "@type": "Question", "name": "Les vaccinations peuvent-elles prévenir des complications ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vaccinations peuvent réduire le risque d'infections chez les patients immunodéficients." } }, { "@type": "Question", "name": "Quels traitements existent pour les déficiences en recombinases ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les thérapies géniques et les traitements immunologiques sont des options possibles." } }, { "@type": "Question", "name": "Peut-on corriger les anomalies des recombinases par des médicaments ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de médicaments spécifiques pour corriger ces anomalies." } }, { "@type": "Question", "name": "La thérapie génique est-elle efficace pour les troubles liés aux recombinases ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des études montrent des résultats prometteurs, mais des recherches supplémentaires sont nécessaires." } }, { "@type": "Question", "name": "Les traitements préventifs sont-ils disponibles pour les troubles de recombinases ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de traitements préventifs, mais un suivi médical régulier est recommandé." } }, { "@type": "Question", "name": "Les greffes de cellules souches peuvent-elles aider ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent être bénéfiques pour certains patients avec des troubles immunitaires liés." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des troubles de recombinases ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des infections récurrentes, des cancers et des troubles auto-immuns sont possibles." } }, { "@type": "Question", "name": "Les troubles de recombinases augmentent-ils le risque de cancer ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des mutations dans les gènes de recombinases sont souvent associées à divers cancers." } }, { "@type": "Question", "name": "Comment les troubles de recombinases affectent-ils la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent entraîner des limitations physiques, des hospitalisations fréquentes et des douleurs." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "Les troubles de recombinases peuvent-ils affecter la fertilité ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains troubles peuvent avoir un impact sur la fertilité, nécessitant une évaluation." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les troubles de recombinases ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des antécédents familiaux de maladies génétiques et des mutations spécifiques augmentent le risque." } }, { "@type": "Question", "name": "L'exposition à des agents environnementaux influence-t-elle les troubles ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains agents environnementaux peuvent augmenter le risque de mutations génétiques." } }, { "@type": "Question", "name": "Les facteurs génétiques jouent-ils un rôle dans les troubles de recombinases ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des mutations héréditaires dans les gènes de recombinases sont souvent impliquées." } }, { "@type": "Question", "name": "Le sexe influence-t-il le risque de troubles de recombinases ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines conditions peuvent être plus fréquentes chez un sexe, mais cela varie selon les maladies." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque pour les troubles de recombinases ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains troubles peuvent se manifester plus tard dans la vie, augmentant le risque avec l'âge." } } ] } ] }

Sources (10000 au total)

Comparing a head-mounted virtual reality perimeter and the Humphrey Field Analyzer for visual field testing in healthy and glaucoma patients.

To compare clinical visual field outputs in glaucoma and healthy patients returned by the Humphrey Field Analyzer (HFA) and virtual reality (Virtual Field, VF) perimetry.... One eye of 54 glaucoma patients and 41 healthy subjects was prospectively tested (three times each in random order) using the HFA and VF perimeters (24-2 test grids). We extracted and compared global ... The VF test was shorter (by 76 s) and had lower fixation losses (by 0.08) and false-positive rate (by 0.01) compared to the HFA (all p < 0.0001). Intraclass correlations were 0.86, 0.82 and 0.47 for M... Virtual Field returns global results that are correlated with the HFA, but pointwise sensitivities were more variable. Differences in test-retest variability and defect detection by its current normat...

Smoking Cessation May Reduce Risk of Visual Field Progression in Heavy Smokers.

The earlier a person quits smoking the more likely is the optic nerve be spared from damage.... To investigate the effect of smoking cessation on visual field (VF) progression in glaucoma.... Primary open angle glaucoma patients with a minimum of 3 years follow-up and 5 VFs were included. Linear mixed models were used to investigate the effects of smoking on the rates of 24-2 VF mean devia... Five hundred eleven eyes of 354 patients were included over the mean follow-up of 12.4 years. Mean baseline age (95% confidence interval) was 62.3 (61.2, 63.4) years. One hundred forty nine (42.1%) pa... After ≥25 years of smoking cessation, the risk of VF progression in former heavy smokers becomes similar to never smokers. Long-term smoking cessation may be associated with lower VF progression in gl...

Predicting 60-4 visual field tests using 3D facial reconstruction.

Despite, the potential clinical utility of 60-4 visual fields, they are not frequently used in clinical practice partly, due to the purported impact of facial contour on field defects. The purpose of ... Subjects with no ocular pathology were included. Participants were subject to optical coherence tomography, 60-4 Swedish interactive thresholding algorithm visual field tests and photography. The pred... 30 healthy were enrolled. Three-dimensional facial reconstruction using a convolution neural network (CNN) was able to predict facial contour-dependent 60-4 visual field defects in 30 subjects without... This pilot study reports the development of a CNN-enhanced platform capable of predicting 60-4 visual field defects in healthy controls based on facial contour. Further study with this platform may en...

Long-Term Visual Field Outcomes After Ahmed Glaucoma Valve Implantation.

To measure visual field (VF) rates of change after Ahmed Glaucoma Valve (AGV) implantation and to investigate risk factors for progression.... Retrospective, clinical cohort study.... Patients who underwent AGV implantation with at least 4 eligible postoperative VFs and 2 years of follow-up were included. Baseline, intraoperative, and postoperative data were collected. VF progressi... A total of 173 eyes were included. The intraocular pressure (IOP) and number of glaucoma medications were significantly reduced from a median (interquartile range [IQR]) of 23.5 (12.1) mm Hg at baseli... To our knowledge, this is the largest published series reporting long-term VF outcomes after glaucoma drainage device implantation. There is a continued, significant rate of VF decline after AGV surge...

Correlation between Interocular Asymmetry of Corneal Hysteresis and Visual Field Defect in Glaucoma.

To evaluate the relationship between interocular asymmetries of corneal hysteresis (CH) and visual field defects in Korean patients with glaucoma.... A total of 444 eyes from 222 participants with glaucoma in at least one eye were enrolled. CH was measured using an ocular response analyzer (Reichert Technologies Inc). Eyes of each participant were ... Median (interquartile range) MD value was -3.71 dB (-6.87 to -1.30 dB) in the better eye and -10.20 dB (-16.32 to -5.62 dB) in the worse eye. When the correlation between the asymmetry of the MD value... The interocular asymmetry of CH was significantly correlated with the interocular asymmetry of visual field defects in glaucoma....

Comparing the Accuracy of Peripapillary OCT Scans and Visual Fields to Detect Glaucoma Worsening.

To compare the accuracy of detecting moderate and rapid rates of glaucoma worsening over a 2-year period with different numbers of OCT scans and visual field (VF) tests in a large sample of glaucoma a... Descriptive and simulation study.... The OCT sample comprised 12 150 eyes from 7392 adults with glaucoma or glaucoma suspect status followed up at the Wilmer Eye Institute from 2013 through 2021. The VF sample comprised 20 583 eyes from ... Within-eye rates of change in retinal nerve fiber layer (RNFL) thickness and mean deviation (MD) were measured using linear regression. For each measured rate, simulated measurements of RNFL thickness... The accuracy of diagnosing moderate and rapid rates of glaucoma worsening for different numbers of OCT scans and VF tests over a 2-year period.... Accuracy was less than 50% for both OCT and VF when diagnosing worsening after a 2-year period. OCT accuracy was 5 to 10 percentage points higher than VF accuracy at detecting moderate worsening and 1... More frequent OCT scans and VF tests are needed to improve the accuracy of diagnosing glaucoma worsening. Accuracy greatly increases when relying on both OCT and VF to detect worsening.... The author(s) have no proprietary or commercial interest in any materials discussed in this article....